(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...
By Samuel Indyk and Ludwig Burger (Reuters) -Shares of major U.S. drugmakers fell on Friday after U.S. President-elect Donald ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback